Safety and immunogenicity of palivizumab (Synagis) administered for two seasons

Pediatric Infectious Disease Journal

Volumn 24, Issue 11, 2005, Pages 1021-1023

  Null Jr , Donald ^a   Pollara, Bernard ^b   Dennehy, Penelope H ^c   Steichen, Jean ^d   Sanchez, Pablo J ^e   Givner, Laurence B ^f   Carlin, David ^g   Landry, Bernard ^g   Top Jr , Franklin H ^g   Connor, Edward ^g  

^a PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g MEDIMMUNE   (United States)

Author keywords

Monoclonal antibody; Palivizumab; Respiratory syncytial virus; Synagis

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PALIVIZUMAB; PLACEBO;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMMUNOGENICITY; IMMUNOREACTIVITY; INFANCY; INFANT; INFECTION PREVENTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SEASON; SIDE EFFECT; SYSTEMIC DISEASE; VIRUS INFECTION; WINTER;

EID: 28044466643     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000183938.33484.bd     Document Type: Article

References (8)

1. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics. 1988;82:199-203.
2. Wang EE, Law BJ, Stephens D. Pediatric investigators collaborative network on infections in Canada (PICNIC): prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr. 1995;126:212-219.
3. Johnson S, Oliver C, Prince G, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997;176:1215-1224.
4. Sáez-Llorens X, Castaño E, Null D, et al. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J. 1998;17:787-791.
5. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531-537.
6. Subramanian KNS, Weisman LE, Rhodes T, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J. 1998;17:110-115.
7. Feltes TF, Cabalka AK, Meissner C, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532-540.
8. Lacaze-Masmonteil T, Seidenberg J, Mitchell I, et al. Evaluation of the safety of palivizumab in the second season of exposure in young children at risk of severe respiratory syncytial virus infection. Drug Safety. 2003;26:283-291.